{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:25:51Z","timestamp":1783416351554,"version":"3.54.6"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin\/kexin type 9.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048919","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:01:57Z","timestamp":1779469317000},"page":"e48919","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Wenzhi","family":"Du","sequence":"first","affiliation":[{"name":"Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Mass Spectrometry Research Institute, Beijing Gobroad Healthcare Group, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Maternal and Child Health Care Hospital of Shandong Province, Jinan, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianning","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6983-0799","authenticated-orcid":false,"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/ph17070919","article-title":"Oral nanoformulations in cardiovascular medicine: advances in atherosclerosis treatment.","volume":"17","author":"Sun","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1126\/science.111.2877.166","article-title":"The role of lipids and lipoproteins in atherosclerosis.","volume":"111","author":"Gofman","year":"1950","journal-title":"Science"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/eurjpc\/zwae240","article-title":"Early onset atherosclerotic cardiovascular disease.","volume":"32","author":"Mousavi","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1002\/mco2.651","article-title":"Endothelial dysfunction: molecular mechanisms and clinical implications.","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm (2020)"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/eurheartj\/ehad304","article-title":"Novel mechanisms and therapeutic targets in atherosclerosis: inflammation and beyond.","volume":"44","author":"Weber","year":"2023","journal-title":"Eur Heart J"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","article-title":"Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.","volume":"52","author":"Zheng","year":"2020","journal-title":"Nat Genet"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications.","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","article-title":"Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs.","volume":"21","author":"Ochoa","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41576-021-00387-z","article-title":"Advancing the use of genome-wide association studies for drug repurposing.","volume":"22","author":"Reay","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"Suppl 4","key":"R10-20260707","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2164-15-S4-S5","article-title":"GWAS and drug targets.","volume":"15","author":"Cao","year":"2014","journal-title":"BMC Genomics"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.drudis.2019.03.024","article-title":"Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities.","volume":"24","author":"Jhamb","year":"2019","journal-title":"Drug Discov Today"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3390\/biomedicines12061204","article-title":"Uncovering druggable targets in aortic dissection: an association study integrating mendelian randomization, pQTL, and protein-protein interaction network.","volume":"12","author":"Jiang","year":"2024","journal-title":"Biomedicines"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1093\/brain\/awad070","article-title":"Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.","volume":"146","author":"Lin","year":"2023","journal-title":"Brain"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCRESAHA.117.312086","article-title":"Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease.","volume":"122","author":"van der Harst","year":"2018","journal-title":"Circ Res"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41593-021-00886-6","article-title":"Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders.","volume":"24","author":"Yang","year":"2021","journal-title":"Nat Neurosci"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"eabj1541","DOI":"10.1126\/science.abj1541","article-title":"Mapping the proteo-genomic convergence of human diseases.","volume":"374","author":"Pietzner","year":"2021","journal-title":"Science"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","article-title":"Large-scale integration of the plasma proteome with genetics and disease.","volume":"53","author":"Ferkingstad","year":"2021","journal-title":"Nat Genet"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41380-022-01507-9","article-title":"Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood.","volume":"27","author":"Deng","year":"2022","journal-title":"Mol Psychiatry"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/aje\/kwt084","article-title":"Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators.","volume":"178","author":"Pierce","year":"2013","journal-title":"Am J Epidemiol"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","article-title":"Genomic atlas of the human plasma proteome.","volume":"558","author":"Sun","year":"2018","journal-title":"Nature"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"e1006706","DOI":"10.1371\/journal.pgen.1006706","article-title":"Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease.","volume":"13","author":"Folkersen","year":"2017","journal-title":"PLoS Genet"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.1","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023.","volume":"4","author":"Burgess","year":"2019","journal-title":"Wellcome Open Res"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1093\/bioinformatics\/btz469","article-title":"PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations.","volume":"35","author":"Kamat","year":"2019","journal-title":"Bioinformatics"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R26-20260707","doi-asserted-by":"crossref","first-page":"14357","DOI":"10.1038\/ncomms14357","article-title":"Connecting genetic risk to disease end points through the human blood plasma proteome.","volume":"8","author":"Suhre","year":"2017","journal-title":"Nat Commun"},{"key":"R27-20260707","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41467-018-05512-x","article-title":"Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease.","volume":"9","author":"Yao","year":"2018","journal-title":"Nat Commun"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41588-018-0184-y","article-title":"Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.","volume":"50","author":"Zhou","year":"2018","journal-title":"Nat Genet"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1038\/s41467-019-11954-8","article-title":"Genetic architecture of human plasma lipidome and its link to cardiovascular disease.","volume":"10","author":"Tabassum","year":"2019","journal-title":"Nat Commun"},{"key":"R31-20260707","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12916-021-02087-1","article-title":"Genome-wide analysis of blood lipid metabolites in over 5000 South Asians reveals biological insights at cardiometabolic disease loci.","volume":"19","author":"Harshfield","year":"2021","journal-title":"BMC Med"},{"key":"R32-20260707","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-024-07148-y","article-title":"Genome-wide characterization of circulating metabolic biomarkers.","volume":"628","author":"Karjalainen","year":"2024","journal-title":"Nature"},{"key":"R33-20260707","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","article-title":"A cross-population atlas of genetic associations for 220 human phenotypes.","volume":"53","author":"Sakaue","year":"2021","journal-title":"Nat Genet"},{"key":"R34-20260707","doi-asserted-by":"crossref","first-page":"e3001547","DOI":"10.1371\/journal.pbio.3001547","article-title":"Characterising metabolomic signatures of lipid-modifying therapies through drug target Mendelian randomisation.","volume":"20","author":"Richardson","year":"2022","journal-title":"PLoS Biol"},{"key":"R35-20260707","doi-asserted-by":"crossref","first-page":"e0182115","DOI":"10.1371\/journal.pone.0182115","article-title":"Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.","volume":"12","author":"Yeo","year":"2017","journal-title":"PLoS One"},{"key":"R36-20260707","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis.","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R37-20260707","doi-asserted-by":"crossref","first-page":"e1001383","DOI":"10.1371\/journal.pmed.1001383","article-title":"Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts.","volume":"10","author":"Vimaleswaran","year":"2013","journal-title":"PLoS Med"},{"key":"R38-20260707","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1038\/s41467-024-50385-y","article-title":"A robust cis-Mendelian randomization method with application to drug target discovery.","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"R39-20260707","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a).","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"R40-20260707","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031023-100609","article-title":"LP(a): structure, genetics, associated cardiovascular risk, and emerging therapeutics.","volume":"64","author":"Tasdighi","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R41-20260707","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R42-20260707","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans.","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"R43-20260707","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"R44-20260707","first-page":"e65","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Alkhalil","year":"2020","journal-title":"N Engl J Med"},{"key":"R45-20260707","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease.","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"R46-20260707","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/01.ATV.0000137288.82390.04","article-title":"The mystery of PCSK9.","volume":"24","author":"Attie","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R47-20260707","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients.","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R48-20260707","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/ars.2014.6054","article-title":"Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.","volume":"22","author":"Ding","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"R49-20260707","doi-asserted-by":"crossref","first-page":"23385","DOI":"10.1074\/jbc.M115.642991","article-title":"Plasma membrane tetraspanin CD81 complexes with proprotein convertase subtilisin\/kexin type 9 (PCSK9) and low density lipoprotein receptor (LDLR), and its levels are reduced by PCSK9.","volume":"290","author":"Le","year":"2015","journal-title":"J Biol Chem"},{"key":"R50-20260707","doi-asserted-by":"crossref","first-page":"152163","DOI":"10.1155\/2013\/152163","article-title":"LRP-1: a checkpoint for the extracellular matrix proteolysis.","volume":"2013","author":"Etique","year":"2013","journal-title":"Biomed Res Int"},{"key":"R51-20260707","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","article-title":"Plasma proprotein convertase subtilisin kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults.","volume":"25","author":"Chan","year":"2016","journal-title":"Heart Lung Circ"},{"key":"R52-20260707","first-page":"5129","article-title":"PCSK9 inhibitors suppress oxidative stress and inflammation in atherosclerotic development by promoting macrophage autophagy.","volume":"15","author":"Yang","year":"2023","journal-title":"Am J Transl Res"},{"key":"R53-20260707","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease.","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacol Ther"},{"key":"R54-20260707","doi-asserted-by":"crossref","first-page":"100578","DOI":"10.1016\/j.jlr.2024.100578","article-title":"APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries.","volume":"65","author":"Yang","year":"2024","journal-title":"J Lipid Res"},{"key":"R55-20260707","doi-asserted-by":"crossref","first-page":"e172600","DOI":"10.1172\/JCI172600","article-title":"Hypertriglyceridemia in Apoa5-\/- mice results from reduced amounts of lipoprotein lipase in the capillary lumen.","volume":"133","author":"Yang","year":"2023","journal-title":"J Clin Invest"},{"key":"R56-20260707","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1515\/cclm-2022-0189","article-title":"Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment.","volume":"60","author":"Wieczorek","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"R57-20260707","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mcp.2014.10.002","article-title":"Association of USF1 and APOA5 polymorphisms with familial combined hyperlipidemia in an Italian population.","volume":"29","author":"Di Taranto","year":"2015","journal-title":"Mol Cell Probes"},{"key":"R58-20260707","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12916-020-01778-5","article-title":"Mendelian randomization study of inflammatory bowel disease and bone mineral density.","volume":"18","author":"Wu","year":"2020","journal-title":"BMC Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:06Z","timestamp":1783414866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":57,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048919","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-10-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}